Veradermics MANE
NYSE MANE
$121.33 +3.51 (+2.98%)
As of: Sep 30, 2026 · 3:59 PM EDT

Veradermics (MANE) Cash from Operations (2025 - 2026)

Updated

Veradermics (MANE) reported Cash from Operations of -$14.5 million for Q2 2026, compared with -$15.68 million a year earlier.

Analysis

Veradermics (MANE) Cash from Operations (2025 - 2026) Analysis & Trends

Over the twelve months ended Jun 30, 2026, Veradermics' Cash from Operations came in at -$64.7 million; for FY2025, it was -$71.6 million.

  • By year, Cash from Operations came in at -$23.7 million in FY2024.
  • The Q2 2026 figure ranks as the highest quarterly Cash from Operations since Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 8.62 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 3.44 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn 5.37 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 5.88 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 4.58 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 4.00 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn 3.57 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 835.00 Mn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 1.13 Bn
10 Veradermics 4.92 Bn 4.92 Bn - -14.50 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -14.50 Mn
Mar 31, 2026 -21.20 Mn
Jun 30, 2025 -15.68 Mn
Mar 31, 2025 -13.32 Mn
API Access

Veradermics Cash from Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-operations&ticker=MANE&period=max&api_key=YOUR_API_KEY